Chugai is the number 1 Japanese bio-pharmaceutical company, founded in Tokyo in 1925, with a large global presence. We have approximately 6,800 employees with ¥72,967,000,000 capital and a revenue of ¥373,517,000.
http://chugai-pharm.co.uk/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Tuesday
LOAD TIME
3.6 seconds
16x16
PAGES IN
THIS WEBSITE
11
SSL
EXTERNAL LINKS
18
SITE IP
194.203.158.23
LOAD TIME
3.625 sec
SCORE
6.2
Chugai Pharma UK | chugai-pharm.co.uk Reviews
https://chugai-pharm.co.uk
Chugai is the number 1 Japanese bio-pharmaceutical company, founded in Tokyo in 1925, with a large global presence. We have approximately 6,800 employees with ¥72,967,000,000 capital and a revenue of ¥373,517,000.
chugai-pharm.co.uk
Chugai Pharma UK - Products - Adverse Event Reporting
http://www.chugai-pharm.co.uk/products/adverse-event-reporting
Company Values and Vision. Supportive Care in Cancer. Chugai Pharma UK - Products - Adverse Event Reporting. Reporting suspected adverse drug reactions. The Yellow Card Scheme is run by the Medicines and Healthcare products Regulatory Agency (MHRA) and Commission on Human Medicines (CHM). Both health professionals and patients can submit information through the Yellow Card website. Further information is available on the Yellow Card website. Report an Adverse Reaction to Chugai Pharma UK Ltd.
Chugai Pharma UK - Products
http://www.chugai-pharm.co.uk/products
Company Values and Vision. Supportive Care in Cancer. Chugai Pharma UK - Products. RoActemra Concentrate for Solution for Infusion (tocilizumab). RoActemra, in combination with methotrexate (MTX), is indicated for. The treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX. The treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have resp...
Chugai Pharma UK - Therapy Areas
http://www.chugai-pharm.co.uk/therapy-areas
Company Values and Vision. Supportive Care in Cancer. Chugai Pharma UK - Therapy Areas. Our Therapy Areas are:. Supportive Care in Cancer. Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Chugai Pharma UK Ltd., on [email protected].
Chugai Pharma UK - About Us - Partnering
http://www.chugai-pharm.co.uk/about-us/partnering
Company Values and Vision. Supportive Care in Cancer. Chugai Pharma UK - About Us - Partnering. Chugai Pharma Marketing LTD (CPM) is the headquarters for all of Chugai’s European commercial activity. CPM is currently seeking late phase or launched Oncology/Haematology products, especially those used in the area of supportive care of patients. We have established strong relationships with Oncology and Haematology key opinion leaders and national study groups in European markets.
Chugai Pharma UK - Careers
http://www.chugai-pharm.co.uk/careers
Company Values and Vision. Supportive Care in Cancer. Chugai Pharma UK - Careers. We want to be outstanding, not only as an innovative company with a distinctive reputation but also as a progressive, responsible and supportive employer. And for us, it’s not just about what we do and what we achieve… it’s about how we do things that’s as important. So our values help to shape and guide our actions and behaviours collectively and individually on a daily basis. If you want to be part of our outstanding team...
TOTAL PAGES IN THIS WEBSITE
11
Home - healthcare professional
http://www.racentral.co.uk/home-healthcare-professional.html
Click here to view the RoACTEMRA website. Click here to view the RoACTEMRA PI. Click here for important upcoming dates for your calendar. News and updates in RA and GPA/MPA. Find out more on the latest news and updates in the RA therapy area. Click here to view the MabThera website. Click here to view the MabThera PI. Roche data on file RXUKMABR00484, 2014; Roche data on file RXUKACTE00042, 2014; Hochberg M. Epidemiol Rev 1981;3:27-44. This website is designed solely for UK Health Care professionals.
Chugai Pharma Europe Ltd :: Products
http://www.chugai.co.uk/products
Chugai Pharmaceutical Co., Ltd. (Parent Company). Chugai Pharma USA, LLC. The primary focus of all Chugai Pharmacetical's activities is to serve patients by developing products that address unmet medical needs and improve lives. CPE do not undertake any commercial, marketing or promotional activities in the UK, these activities are performed by Chugai Pharma UK Ltd, for more information on marketed products please visit their website using the following link. Chugai Pharma UK Ltd.
REMISSION IS THE GOAL-NOT TO USE
http://www.roactemra.co.uk/home/remission/remission-is-the-goal_old.html
REMISSION IS THE GOAL. REMISSION IS THE GOAL. Is a 1.2 DAS28 reduction good enough? A small improvement isn’t enough. Remission is the goal. Sustained remission must be the ultimate goal of treatment for your RA patients (NCCCC, 2009; Smolen et al. 2014; Aletaha et al. 2009). Click here to view the NICE guidelines. 2013 NICE Quality Standards in RA. Your patients’ pathway (NICE Quality Standards 33, 2013). Got a question about RoACTEMRA? Check out our FAQs. We use cookies to give you a better experience&...
REMISSION IS THE GOAL
http://www.roactemra.co.uk/home/remission/remission-is-the-goal.html
REMISSION IS THE GOAL. REMISSION IS THE GOAL. Is a 1.2 DAS28 reduction good enough? A small improvement isn’t enough. Remission should be the goal. Sustained remission must be the ultimate goal of treatment for your RA patients (NCCCC, 2009; Smolen et al. 2014; Aletaha et al. 2009). A small improvement isn’t enough. Remission is the goal. Sustained remission must be the ultimate goal of treatment for your RA patients (NCCCC, 2009; Smolen et al. 2014; Aletaha et al. 2009). 2013 NICE Quality Standards in RA.
EFFICACY SC
http://www.roactemra.co.uk/home/efficacy/efficacy_sc.html
Nearly 4 times more patients achieved remission with RoACTEMRA IV monotherapy compared with HUMIRA monotherapy (Gabay et al. 2013)*. RoACTEMRA now offers efficacy in achieving remission with the convenience and flexibility of subcutaneous injection (RoACTEMRA SC SmPC, 2014). 67% of patients were MTX naïve. Can I take my RoACTEMRA at home? Is RoACTEMRA subcut as effective as IV? Could I reach remission with RoACTEMRA subcut? Summary of Product Characteristics. Click here to view RoACTEMRA’s SC SmPC. Befor...
REMISSION IS THE GOAL
http://www.roactemra.co.uk/home/remission.html
REMISSION IS THE GOAL. REMISSION IS THE GOAL. Is a 1.2 DAS28 reduction good enough? A small improvement isn’t enough. Remission should be the goal. Sustained remission must be the ultimate goal of treatment for your RA patients (NCCCC, 2009; Smolen et al. 2014; Aletaha et al. 2009). A small improvement isn’t enough. Remission is the goal. Sustained remission must be the ultimate goal of treatment for your RA patients (NCCCC, 2009; Smolen et al. 2014; Aletaha et al. 2009). 2013 NICE Quality Standards in RA.
TREATMENT ACCESS
http://www.roactemra.co.uk/home/treatment_access.html
Patients should be offered the treatment option that maximises their chance of sustained remission. NICE recommends RoACTEMRA in combination with methotrexate as a treatment option for adult RA patients with active disease (NICE TA247, 2012) if:. The disease has responded inadequately to one or more disease-modifying anti-rheumatic drugs (DMARDs). The disease has responded inadequately to one or more TNF inhibitor treatments and to MabThera. NICE are currently reviewing the clinical and cost effectivenes...
PATIENT ID
http://www.roactemra.co.uk/home/patient-id/patient-id.html
Methotrexate (MTX) is a standard of care in RA, and a well-established guideline recommended therapy (Smolen et al. 2014). It is the initial treatment choice for both active RA, and also in combination with biologics for DMARD-IR patients (Smolen et al. 2014). But MTX is not appropriate for everyone (Choquette et al. 2012). We just can’t take our MTX anymore, and we might not tell you. Why I might not take my MTX. Click here to order our non-adherence discussion guide. Click here for more information.
NEWSLETTER SUBSCRIPTION
http://www.roactemra.co.uk/home/NEWSLETTER_SUBSCRIPTION1/newsletter_subscription1.html
Want to stay informed? Sign up to our RA Newsletter. For this purpose please supply the following information. Personal Information collected on this form will only be used for the purposes highlighted above and will not be disclosed to any third party without your written consent. The information will be kept securely and will be kept no longer than necessary. All information, including any 'sensitive data' will be held and processed within the terms of the Data Protection Act 1998. I am not a HCP.
TOTAL LINKS TO THIS WEBSITE
18
株式会社中外燐寸社
戦前および戦後１０余年あたりまでのマッチの製造過程では、亜硫酸ガスが発生していましたが、それが原因で、４代目社長 前社長 の母親は喘息 ぜんそく になったそうです。 また、１９６０ １９７２年当時社会問題となった 四日市ぜんそく公害訴訟 もあって、前社長は マッチの主成分であるイオウを使わないマッチを作ろう。 今後も 環境にやさしい製品 身体にやさしい製品 を目標に、マッチ一本一本に心を込めて皆様方にお届けいたします。
中外製薬株式会社 採用サイト 製薬業界をリードする存在として、医療の未来に貢献していく。
患者さん・一般の皆さま｜中外製薬
中外製薬株式会社｜創造で、想像を超える。
中外製薬の支援制度 研究/教育啓発 患者団体 活動. 中外製薬の支援制度 研究/教育啓発 患者団体 活動. AYA Life -あや ライフ-. 中外製薬の支援制度 研究/教育啓発 患者団体 活動. 2018/02/20 健康経営優良法人2018 大規模法人部門 〜ホワイト500〜 に認定されました. 2017/10/30 報道関係者向けに CEO説明会 を開催しました. Src="/images/carousel nav right.png".
Chugai Pharma UK
Company Values and Vision. Supportive Care in Cancer. Welcome to Chugai Pharma UK Ltd. A warm welcome to the Chugai Pharma UK website. Chugai is the number 1 Japanese bio-pharmaceutical company, founded in Tokyo in 1925, with a large global presence. We have approximately 6,800 employees with ¥73 billion capital and a revenue of ¥424 million. We look for win-win solutions in all our business relationships which in essence makes things happen. Transparency Declaration on 2014 Spend on UK HCPs.
Chugai Pharma USA, Inc. :: Home
Skip To Voice Support Menu. Senior Manager/Associate Director Regulatory Affairs. Chugai Pharma USA, LLC is now Chugai Pharma USA, Inc. Aug 11, 2015 Caution Regarding False Solicitations on Behalf of Chugai. May 14, 2015 Warning against Phishing e-mails and social networking sites using the name of Chugai Pharmaceutical. Long-Acting Erythropoiesis Stimulating Agent MIRCERA Injection Syringe 12.5μg Approved in Japan. Chugai Decided as 2017 Tokyo Sports Promotion Model Company. Video Introduction of CHUGAI.
医療従事者向け｜中外製薬
エディロールカプセル0.5μg、0.75μg PTPシート、個別箱等変更のご案内. エポジン注シリンジ アンプル、エポジン皮下注シリンジ アンプル ピシバニール注射用 添付文書改訂のお知らせ. アルサルミン細粒、カルフェニール錠、ジゴシン散 錠、ピドキサール錠 注、プロパジール錠、メルカゾール錠 添付文書改訂のお知らせ. コペガス錠200mg 効能 効果、用法 用量追加のご案内. アルサルミン細粒、カルフェニール錠、ジゴシン散、ピドキサール錠 注、プロパジール錠、メルカゾール錠 新包装発売 一部包装販売中止 包装仕様変更のご案内.
Chugai Pharma USA, LLC :: Home
Error Page cannot be displayed. Please contact your service provider for more details. (25).
Chugai Pharmabody
Global Chugai News Release. Tuesday, 20 March 2018 6:00 AM. Long-Acting Erythropoiesis Stimulating Agent MIRCERA Injection Syringe 12.5μg Approved in Japan. Friday, 16 March 2018 6:45 AM. Chugai Decided as 2017 Tokyo Sports Promotion Model Company. Friday, 16 March 2018 6:00 AM. Chugai Starts Activities towards Commercialization of Foundation Medicine’s Products in Japan - Chugai Enters a License Agreement with Roche and Submits for Regulatory Approval of FoundationOne CDx™ -. 3 Biopolis Drive,.
